551 related articles for article (PubMed ID: 24912948)
1. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
Hato T; Goyal L; Greten TF; Duda DG; Zhu AX
Hepatology; 2014 Nov; 60(5):1776-82. PubMed ID: 24912948
[TBL] [Abstract][Full Text] [Related]
2. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
Harding JJ
Future Oncol; 2018 Sep; 14(22):2293-2302. PubMed ID: 29663837
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
Harding JJ; El Dika I; Abou-Alfa GK
Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors for hepatocellular carcinoma.
El Dika I; Khalil DN; Abou-Alfa GK
Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
[TBL] [Abstract][Full Text] [Related]
6. Blockade of PD-1 and CTLA-4: A potent immunotherapeutic approach for hepatocellular carcinoma.
Hou K; Xu X; Ge X; Jiang J; Ouyang F
Biofactors; 2024; 50(2):250-265. PubMed ID: 37921427
[TBL] [Abstract][Full Text] [Related]
7. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for hepatocellular carcinoma.
Zongyi Y; Xiaowu L
Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
10. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
Roth GS; Decaens T
Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
[TBL] [Abstract][Full Text] [Related]
11. Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
Zhongqi F; Xiaodong S; Yuguo C; Guoyue L
Anticancer Agents Med Chem; 2019; 19(2):222-228. PubMed ID: 30426903
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
13. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.
Hou J; Zhang H; Sun B; Karin M
J Hepatol; 2020 Jan; 72(1):167-182. PubMed ID: 31449859
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
Shen KY; Zhu Y; Xie SZ; Qin LX
J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698
[TBL] [Abstract][Full Text] [Related]
15. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges.
Wang L; Wang FS
Hepatol Int; 2019 Sep; 13(5):521-533. PubMed ID: 31352593
[TBL] [Abstract][Full Text] [Related]
16. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
Front Immunol; 2021; 12():765101. PubMed ID: 34675942
[TBL] [Abstract][Full Text] [Related]
18. Novel immunotherapy strategies for hepatobiliary cancers.
DeLeon TT; Zhou Y; Nagalo BM; Yokoda RT; Ahn DH; Ramanathan RK; Salomao MA; Aqel BA; Mahipal A; Bekaii-Saab TS; Borad MJ
Immunotherapy; 2018 Sep; 10(12):1077-1091. PubMed ID: 30185133
[TBL] [Abstract][Full Text] [Related]
19. [Advances in the study of programmed cell death protein 1 and its ligand inhibitors in the treatment of late stage HCC].
Xiao ZL; Wang P; Lei LP; Zhou HB; Hu HP
Zhonghua Gan Zang Bing Za Zhi; 2019 Sep; 27(9):732-736. PubMed ID: 31594104
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
